Our Group

Making everyday life better for everyone and improving the health and well-being of all.

MAYOLY relies on an agile and committed corporate governance structure to support its long-term viability and sustainable, responsible value creation. The Executive Committee steers the Group’s growth trajectory and implements its strategy.

Meeting monthly, it steers strategic projects, sets objectives, decides on priorities and monitors the performance and results of the various entities. The Executive Committee ensures the smooth running of the Group.

The Executive Committee comprises the Managing Director, the Executive Vice-President Global Sales, the Executive Vice-President Dermocosmetics, the Executive Vice-President Marketing CHC, the Executive Vice-President Finance and Administration, the Executive Vice-President Industrial Operations, the Executive Vice-President Strategy, Innovation & Business Transformation, the Executive Vice-President Human Relations, Communication and CSR, the Executive Vice-President M&A, BD and Alliances and the Vice-President Legal Affairs, Risks and Compliance.

The Executive Committee

Nicolas GIRAUD

CEO

Sophie DESLOGES

EVP Chief Financial Officer

Emmanuel PAINT

EVP Global Sales

Roberto NAKAHARA

EVP Global Marketing CHC

Vincent BERCOVICI

EVP Dermocosmetics

Sébastien NICOLAS

EVP Industrial Operations

Alexandre FUZIER

EVP Strategy, Innovation & Business Transformation

Christophe NAPIOT

EVP Human Relations, Communication and CSR

Gael CHALVON-DEMERSAY

EVP Fusions & Acquisitions, Business Developement et Alliances

Our products are distributed in over 100 countries.

• Consumer health Care: Smecta®, Forlax®, MeteoSpasmyl®, Tanakan®, Probiolog®, Topicrem
• Prescription: Fortrans®, Eziclen®…
• Diagnostic: Helikit, Diabact, Kibion Dynamic…

A family history spanning more than a century.

Founded in 1909 by pharmacist Louis-Charles Vernin, Laboratoires Galéniques Vernin originally manufactured plant-based medicines for the health and cosmetics industries.

In 1929, a couple of pharmacists founded Laboratoires Mayoly Spindler.

The years that followed were punctuated by numerous launches and events, which can be grouped into 3 major periods:

From 1930 to 1982, with the launch of Euphon®, Pérubore®, Borostyrol® and Baume Arôma®, followed by the launch of Methiospasmyl™ in 1964 and Charlieu® shampoos, and the acquisition of Laboratoires Mayoly Spinder by Jean-Marie Vernin in 1975.

From 1982 to 2008, with the creation of the Dammarie-les-Lys industrial site (1989), the acquisitions of Laboratoires Galéniques Vernin, Rosa-Phytopharma and Opocalcium, not forgetting the launch of the Topicrem® range in 1993, quickly followed by the acquisitions and launches of Helikit®, Eurobiol®, Colchicine® and Colchimax® products, and the launch of the Probiolog® range in 2006.

From 2008, with the launch of Colokit® and Cholurso®, and the succession of Jean-Nicolas Vernin to his father Jean-Gilles Vernin. This period marked an acceleration towards consumer healthcare, with the development of the Probiolog® range and over-the-counter (OTC) medicines, as well as numerous acquisitions such as Biohealth®, Beauterra®, Pharmnature™, and Ipsen’s family healthcare business, which complemented and strengthened MAYOLY’s portfolio in the digestive sphere, notably with the Smecta® brand. This is also a very strong period of internationalization for MAYOLY, which is now present in 21 subsidiaries and markets its products in over 100 countries.

2021, acquisition of BioHealth® in Italy, a company specializing in the design and marketing of dietary supplements in the fields of metabolism and women’s health.

Acquisition of Beauterra®, a cosmetic hygiene brand whose 70 products are produced in France, with a mainly digital sales model.

2022, acquisition of Ipsen’s family health business, which has a broad portfolio of drugs, dietary supplements and medical devices in the gastrointestinal sphere (diarrhea, constipation, colic preparation) and products in other therapeutic areas (pain relief, cognitive disorders, cough).

Acquisition of Pharmnature™, a Breton company specializing in the design and marketing of dietary supplements based on plants and natural ingredients. MAYOLY thus positions itself in new territories with a natural health approach: phytotherapy and oligotherapy.

Our human chemistry is unique.

The fruits of our history and evolution, our values and company culture reflect our shared ambition to become an international leader in Consumer Health.
They strengthen our ability to act, stimulate our creativity, and cultivate a positive mindset every day.
This foundation is much more than a set of values; it is a source of inspiration for every employee at MAYOLY.

3 fundamental commitments to serve of our patients, clients, and consumers.

This core set of values nurtures our company culture, guides our actions on a daily basis and helps us meet the challenges of tomorrow.

An innovative combination of 15 verbs and adverbs, customizable and infinite, that allows each employee, in line with our company culture, to be creative, make decisions, and act in the best interest of all, independently and responsibly.

The Mayoly group has 6 industrial sites, 5 of which are in France, and an international reach with 21 locations.

Our industrial sites are recognized for their operational excellence, and several are ISO 14001 (environment), ISO 45001 (health and safety), ISO 13485 (medical devices) and ISO 50001 (energy) certified.

6 industrial sites :

• Chatou
• Dreux
• Dammarie-les-Lys Pharma
• Dammarie-les-Lys Dermo
• L’Isle-sur-la-Sorgue
• Tianjin

1 Research and Development hub located in Dammarie, France

A French group with a global presence

• Algeria
• Germany
• Belgium
• Belarus
• China
• Spain
• France
• Italy
• Kazakhstan
• Lithuania
• Mexico
• Poland
• Czech Republic
• Romania
• United Kingdom
• Russia
• Singapore
• Slovakia
• Tunisia
• Ukraine
• Vietnam